AIMS/HYPOTHESIS: Insulin resistance is recognised as the core factor in the pathogenesis of Type II (non-insulin-dependent) diabetes mellitus, hypertension and atherosclerosis. Several studies indicate the possible role of mutations of the insulin receptor substrate-1 (IRS-1) gene in the pathogenesis of insulin-resistance and suggest a possible interaction between the IRS-1 gene and obesity, either by an effect on the development of obesity or by causing or aggravating the obesity-associated insulin resistance. Therefore, the prevalence of the G972R mutation of the IRS-1 gene was compared in 157 non-diabetic obese subjects (BMI > 30 m/kg2) and in 157 lean subjects (BMI < 28 m/kg2). By investigating the relation between this IRS-1 mutation, measures of obesity and metabolic parameters, we explored the possible influence of this mutation on body fat distribution and insulin resistance. METHODS: The G972R mutation was detected by PCR amplification and BstN-1 restriction enzyme digestion. Data were analysed by univariate and multivariate analysis. RESULTS: The G972R allele was significantly more frequent in obese subjects than in lean subjects (p < 0.002); however, no difference was found between centrally and peripherally obese subjects. Obese G972R carriers had significantly higher BMI (p < 0.001), fasting insulin (p < 0.001), triglycerides (p < 0.03) and HOMAIR (p < 0.001) than obese non-carriers. No differences were observed between G972R carriers and non-carriers among control subjects. Multivariate analysis confirmed that the IRS-1 G972R mutation was significantly and independently associated with reduced insulin sensitivity (p < 0.009) in the obese group. CONCLUSION/ INTERPRETATION: The G972R mutation of the IRS-1 gene associates with obesity, but not with fat distribution, in this Italian cohort, and within the obese subjects this IRS-1 variant strongly associates with metabolic parameters suggesting greater insulin-resistance. These findings indicate a possible interaction between the IRS-1 variant and obesity in worsening insulin sensitivity.
AIMS/HYPOTHESIS: Insulin resistance is recognised as the core factor in the pathogenesis of Type II (non-insulin-dependent) diabetes mellitus, hypertension and atherosclerosis. Several studies indicate the possible role of mutations of the insulin receptor substrate-1 (IRS-1) gene in the pathogenesis of insulin-resistance and suggest a possible interaction between the IRS-1 gene and obesity, either by an effect on the development of obesity or by causing or aggravating the obesity-associated insulin resistance. Therefore, the prevalence of the G972R mutation of the IRS-1 gene was compared in 157 non-diabetic obese subjects (BMI > 30 m/kg2) and in 157 lean subjects (BMI < 28 m/kg2). By investigating the relation between this IRS-1 mutation, measures of obesity and metabolic parameters, we explored the possible influence of this mutation on body fat distribution and insulin resistance. METHODS: The G972R mutation was detected by PCR amplification and BstN-1 restriction enzyme digestion. Data were analysed by univariate and multivariate analysis. RESULTS: The G972R allele was significantly more frequent in obese subjects than in lean subjects (p < 0.002); however, no difference was found between centrally and peripherally obese subjects. ObeseG972R carriers had significantly higher BMI (p < 0.001), fasting insulin (p < 0.001), triglycerides (p < 0.03) and HOMAIR (p < 0.001) than obese non-carriers. No differences were observed between G972R carriers and non-carriers among control subjects. Multivariate analysis confirmed that the IRS-1G972R mutation was significantly and independently associated with reduced insulin sensitivity (p < 0.009) in the obese group. CONCLUSION/ INTERPRETATION: The G972R mutation of the IRS-1 gene associates with obesity, but not with fat distribution, in this Italian cohort, and within the obese subjects this IRS-1 variant strongly associates with metabolic parameters suggesting greater insulin-resistance. These findings indicate a possible interaction between the IRS-1 variant and obesity in worsening insulin sensitivity.
Authors: Jing Fan; Roberta McKean-Cowdin; Leslie Bernstein; Frank Z Stanczyk; Arthur Xuejun Li; Rachel Ballard-Barbash; Anne McTiernan; Richard Baumgartner; Frank Gilliland Journal: Breast Cancer Res Treat Date: 2006-06-05 Impact factor: 4.872
Authors: José López-Miranda; Pablo Pérez-Martínez; Carmen Marin; Francisco Fuentes; Javier Delgado; Francisco Pérez-Jiménez Journal: J Mol Med (Berl) Date: 2006-12-15 Impact factor: 4.599
Authors: Otto Tschritter; Hubert Preissl; Anita M Hennige; Michael Stumvoll; Katarina Porubska; Rebekka Frost; Hannah Marx; Benjamin Klösel; Werner Lutzenberger; Niels Birbaumer; Hans-Ulrich Häring; Andreas Fritsche Journal: Proc Natl Acad Sci U S A Date: 2006-07-28 Impact factor: 11.205
Authors: Corinne Lautier; Samira Ait El Mkadem; Eric Renard; Jean Frédéric Brun; Jean Christophe Gris; Jacques Bringer; Florin Grigorescu Journal: Hum Genet Date: 2003-04-10 Impact factor: 4.132
Authors: Catherine Duggan; Richard N Baumgartner; Kathy B Baumgartner; Leslie Bernstein; Stephanie George; Rachel Ballard; Marian L Neuhouser; Anne McTiernan Journal: Breast Cancer Res Treat Date: 2017-12-18 Impact factor: 4.872
Authors: M G Baroni; F Leonetti; F Sentinelli; S Romeo; E Filippi; M Fanelli; M C Ribaudo; A Zappaterreno; M Fallarino; U Di Mario Journal: J Endocrinol Invest Date: 2004-09 Impact factor: 4.256
Authors: H Shakeri; A Khoshi; M Kaffash Bajestani; A Farahi; M S Javadzadeh; Z Hosseini; R Mohammadi Journal: Acta Endocrinol (Buchar) Date: 2019 Jul-Sep Impact factor: 0.877